Cannabidiol (CBD) shows promise in regulating appetite, glucose and lipid metabolism, and inflammation in preclinical models of obesity and metabolic syndrome. However, human evidence is still limited, highlighting the need for rigorous trials before clinical use. Read more
Medical News - Sep 30
